N@N

Cubist Pharmaceuticals to Present at September 2011 Investor Conferences

^{Published on 2011-08-29 07:11:41 - Market Wire}
 

LEXINGTON, Mass.--([ BUSINESS WIRE ])--[ Cubist Pharmaceuticals, Inc. ] (NASDAQ: CBST) today announced that company management will present at investor conferences during September 2011 to discuss the companya™s business activities, financial outlook, and current news.

• David McGirr, SVP and CFO, will present on Wednesday, September 7, at 3:15 p.m. Eastern Time, at the RW Baird 2011 Healthcare Conference being held at the Palace Hotel in New York City. ([ Live audio with slides webcast ])
• Steven Gilman, EVP and CSO, will present on Thursday, September 8, at 3:50 p.m. Eastern Time, at the Stifel Nicolaus Healthcare Conference being held at the Four Seasons Hotel in Boston. ([ Live audio with slides webcast ])
• David McGirr, SVP and CFO, will present on Monday, September 19, at 3:30 p.m. Eastern Time, at UBS Global Life Sciences Conference being held at the Grand Hyatt in New York City. ([ Live audio with slides webcast ])

The live webcasts will be accessible through Cubista™s website at [ www.cubist.com ] in the Investor Relations Conference Calendar section and will be available for viewing at that location for 30 days after the presentation.

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides, and has an agreement with Optimer Pharmaceuticals, Inc. to co-promote DIFICIDa" in the U.S. as a treatment of CDAD (Clostridium difficile-associated diarrhea) in adults. The current Cubist clinical development pipeline includes CXA-201, a novel cephalosporin in combination with tazobactam in development for the treatment of certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms. CXA-201 is in Phase 3 trials for complicated urinary tract infections (cUTI), and Cubist expects to initiate Phase 3 trials with CXA-201 in complicated intra-abdominal infections (cIAI) by the end of 2011. In addition, Phase 3 trials of CXA-201 in hospital acquired (nosocomial) pneumonia are expected to begin in 2012. Cubist has completed Phase 2 trials of a novel antibacterial candidate, CB-183,315, for the treatment of CDAD and plans to make a go/no go decision of whether to move CB-183,315 into Phase 3 trials in the third quarter of 2011. Cubist also is working on several pre-clinical programs being developed to address areas of significant medical needs. These include therapies to treat various serious bacterial infections and acute pain. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubista™s web site at [ www.cubist.com ].

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.

DIFICID is a trademark of Optimer Pharmaceuticals, Inc.